{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiaunj4gff2ff764ps2iiym3o2hmbbwwwbfyxlto4bpq24n7ryf7sq",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3menzncmpm2t2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreic76nfb7mf74fcpx4ddj65o7cv4xpvjgqtex64rtacdrziazsd3ee"
    },
    "mimeType": "image/jpeg",
    "size": 47548
  },
  "path": "/2026/02/12/prasad-takes-conservative-approach-rare-disease-drugs-adams-biotech-scorecard/?utm_campaign=rss",
  "publishedAt": "2026-02-12T11:30:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Adam's Biotech Scorecard",
    "Adam's Take",
    "Biotech",
    "drug development",
    "Policy",
    "research",
    "STAT+"
  ],
  "textContent": "Prasad changed jobs but his conservative regulatory doctrine remains the same, particularly for cell and gene therapies. The approval bar is much higher now.",
  "title": "STAT+: The old Vinay Prasad never left. He just changed jobs",
  "updatedAt": "2026-02-12T11:17:51.000Z"
}